A report about an ongoing trial of the drug from Raleigh-based Sprout Pharmaceuticals for treatment of low sexual desire in women finds in interim results that the so called ‘female Viagra’ can “be used safely and effectively in women with breast cancer.”
Read More
Raleigh startup Sprout Pharmaceuticals continues to raise capital – the latest raise of $2.9 million from six more investors puts the total near $28 million.
Read More
Sprout2, the business entity connected to Sprout Pharma, disclosed it has raised more than $25 million in an amended SEC filing this week.
Read More
Sprout Pharma has raised more than $12 million from 64 investors, and could raise more, CEO Cindy Eckert told WRAL TechWire.
Read More
Sprout Pharmaceuticals, which makes the only FDA-approved drug for female sexual disfunction often called “Viagra” for women, has raised a debt round.
Read More
Sprout Pharmaceuticals says data from three clinical trials proves the efficacy of its female sexual disfunction drug Addyi – often called the “female Viagra.”
Read More
Cindy Eckert, CEO of Raleigh-based Sprout Pharmaceuticals, says the next step in an ongoing debate with the Food and Drug Administration about the firm’s female sexual dysfunction drug Addyi is up to the regulatory agency.
Read More
The U.S. Food and Drug Administration says its discussions with Raleigh-based Sprout Pharmaceuticals about its female sexual dysfunction drug Addyi are intended to avoid “confusion” about any changes in warnings regarding the drug’s use.
Read More
The US Food and Drug Administration is saying that the status of warnings about the female sexual dysfunction drug Addyi from Raleigh-based Sprout Pharmaceuticals has not changed. Sprout says it is working to resolve the issue.
Read More
